CellGENTherapies
CellGENTherapies produces advanced gene-, cell- and tissue-therapeutic products (ATMPs) for early phase clinical trials according to good manufacturing principles (GMP).
We focus on the development and production of small batches of ATMPs (including personalized products) and prophylactic RNA vaccines for phase I studies helping UZ Gent, external clients and partners to move their research “from bench to bedside”.
News & Events
-
CellGENTherapies attracted by VIB and KUL
CellGENTherapies is attracted by the VIB and the Katholieke Universiteit Leuven (Prof Dieter Lambrechts) to produce a lipid nanoparticle RNA cancer vaccine using the Galsome technology developed by Ghent Research Group on Nanomedicines (Prof Stefaan De Smedt and Dr Ine Lentacker) for a clinical trial in patients with hepatocellular carcinoma (PI prof Jeroen Dekervel, UZLeuven).…
-
Grant for phase I clinical trial evaluating a personalized mRNA-LNP vaccine in NSCLC
Prof Bart Vandekerckhove, head of the GMP unit ‘CellGENTherapies’ of Ugent and UZ Gent, has received an important grant of €790K from ‘the Stichting Tegen Kanker (STK)’ and ‘Kom op tegen Kanker (KOTK)’, both Belgians associations funding research to improve cancer outcome. The grant will be used to setup a Phase I clinical trial of…
CellGENTherapies is a member of
Vaxadvance is an initiative at Ghent University Hospital driven by four high level expertise centra who have strengthen their forces with the goal to accelerate breakthroughs in vaccine and therapeutic development.
- NanoMedicine Centre: nanoparticle-based formulation services
- the GMP unit CellGENTherapies: GMP production of ATMPs for early phase clinical trials
- the core ARTH Animal Facilities: lab animal-based preclinical research
- the Center for Vaccinology CEVAC: dedicated trial center Phase I – IV and Immuno-monitoring
With Vaxadvance, Ghent University Hospital continues playing a crucial role in driving the future of vaccine innovation.
Partners
Sponsors
